No GLP-1 medication is FDA-approved as a fertility treatment, but a steady stream of anecdotal reports and a growing body of smaller studies have raised genuine questions about how these drugs interact with reproductive health — in both directions. Here's what's actually been studied, and what remains anecdotal.
The "Ozempic Baby" Phenomenon
Since GLP-1 medications became widely prescribed for weight loss, there have been numerous informal reports, mostly shared online and in media coverage, of women becoming unexpectedly pregnant while on both a GLP-1 drug and hormonal birth control. Two separate mechanisms have been proposed. First, significant weight loss and improved insulin sensitivity can restore ovulation in women with obesity-related infertility or polycystic ovary syndrome (PCOS), a well-documented effect of weight loss generally, not something unique to GLP-1 drugs specifically. Second, because GLP-1 drugs slow gastric emptying, there's a theoretical concern that this could reduce the absorption of oral contraceptives, particularly during dose escalation. These reports are illustrative of a possible interaction, not evidence from a controlled clinical trial, and they haven't been confirmed as a direct pharmacological effect at the population level. Even so, out of caution, tirzepatide's FDA label specifically advises that women using oral contraceptives switch to a non-oral method or add a barrier method for four weeks after starting the drug and after each dose increase.
What Research on Fertility and Ovulation Shows
A growing set of smaller studies, including case series and systematic reviews looking at GLP-1 drugs in the context of fertility treatment, have examined whether weight loss and metabolic improvement from these medications can help restore ovulation in women with PCOS or obesity-related infertility. Some of this research, including reports on outcomes in women undergoing IVF, suggests a potential benefit tied to the metabolic and weight-related effects of these drugs. This is a meaningfully different claim than saying GLP-1 drugs directly improve fertility through some reproductive-specific mechanism; the proposed pathway runs through weight loss and improved insulin sensitivity, which are independently associated with improved ovulation in some patients. This research is still early, generally based on smaller or retrospective studies rather than large randomized trials, and GLP-1 drugs are not an approved or established fertility treatment.
Use During Pregnancy and Before Conception
This is the area where the guidance is clearest and most conservative. GLP-1 medications are not recommended during pregnancy. Animal studies of several drugs in this class have shown reproductive toxicity, including effects on fetal growth, at doses relevant to human exposure, and there isn't robust human safety data on GLP-1 use during pregnancy to rule out risk. Because semaglutide in particular has a long half-life, prescribing information for Wegovy and Ozempic recommends discontinuing the drug at least two months before a planned pregnancy to allow it to clear the body. For tirzepatide, the label recommends discontinuation when pregnancy is planned or recognized. Anyone taking a GLP-1 medication who is pregnant, trying to conceive, or thinking about trying to conceive should talk to their prescribing physician or an OB-GYN directly about the specific timeline for stopping the medication and about reliable contraception in the meantime, rather than relying on general guidance like this article.
The Bottom Line
The clearest, best-supported fact here is also the most actionable one: GLP-1 drugs are not approved for use during pregnancy, and current prescribing guidance calls for stopping them well in advance of a planned pregnancy. The fertility-restoring and contraceptive-interaction questions are real areas of ongoing research and informal reporting, but they remain less settled, and neither changes the core recommendation to use reliable contraception while on these medications unless pregnancy is specifically intended and the drug has been appropriately discontinued under a doctor's guidance.